NCT05888103 - Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol. | Biotech Hunter

Enrollment

207

Participants

Timeline

Start Date

July 11, 2023

Primary Completion Date

April 2, 2024

Study Completion Date

October 24, 2024

Conditions

Primary Hypercholesterolemia or Mixed Dyslipidemia

Interventions

DRUG

Inclisiran

Inclisiran s.c

DRUG

Matching Placebo for Inclisiran

Matching s.c. placebo

Trial Locations (28)

100029

Novartis Investigative Site, Beijing

100034

Novartis Investigative Site, Beijing

100730

Novartis Investigative Site, Beijing

101200

Novartis Investigative Site, Beijing

121001

Novartis Investigative Site, Jinzhou

200025

Novartis Investigative Site, Shanghai

200080

Novartis Investigative Site, Shanghai

200120

Novartis Investigative Site, Shanghai

213004

Novartis Investigative Site, Changzhou

221003

Novartis Investigative Site, Xuzhou

250012

Novartis Investigative Site, Jinan

276000

Novartis Investigative Site, Linyi

300052

Novartis Investigative Site, Tianjin

300121

Novartis Investigative Site, Tianjin

300140

Novartis Investigative Site, Tianjin

310006

Novartis Investigative Site, Hangzhou

330009

Novartis Investigative Site, Nanchang

350025

Novartis Investigative Site, Fuzhou

410003

Novartis Investigative Site, Changsha

410011

Novartis Investigative Site, Changsha

430022

Novartis Investigative Site, Wuhan

510000

Novartis Investigative Site, Guangzhou

510515

Novartis Investigative Site, Guangzhou

528403

Novartis Investigative Site, Zhongshan

610041

Novartis Investigative Site, Chengdu

710061

Novartis Investigative Site, Xian

010017

Novartis Investigative Site, Hohhot

030002

Novartis Investigative Site, Taiyuan